What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical progress.
ELVN - Enliven Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$69.20
DETAILS
HIGH:
$80.00
LOW:
$59.00
MEDIAN:
$65.00
CONSENSUS:
$69.20
UPSIDE:
32.62%
Stock News
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
Orbimed Advisors reported selling 860,123 shares of ELVN on June 22, 2026, generating a transaction value of approximately $39.0 million at an average price of $45.36 per share. This transaction represented 11.60% of Advisors Llc Orbimed's total indirect holdings, reducing indirect ownership from 7,415,225 to 6,555,102 shares.
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven's common stock less the $0.001 per share exercise price for each pre-funded warrant.
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PR Newswire
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced upsized underwritten public offering of 8,933,334 shares of its common stock at a price to the public of $37.50 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,733,333 shares of Enliven's common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven's common stock less the $0.001 per share exercise price for each pre-funded warrant.
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock.
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort 67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 prior unique TKIs Favorable safety and tolerability profile with 161 patients enrolled and a median treatment duration of 35 weeks Alignment with the FDA on 80 mg QD as the recommended Phase 3 dose and on the 2L+ patient population for the ENABLE-2 pivotal trial, which is expected to initiate in the second half of this year BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today presented updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia (CML).
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
Enliven will host a webcast conference call on June 11, at 8:30 a.m. ET BURLINGAME, Calif.
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.
This oncology-focused biotech, advancing kinase inhibitors for cancer, reported a notable insider sale amid strong one-year stock gains.
Enliven Therapeutics to Present at Upcoming Investor Conferences
BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences: TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHAFormat: Fireside ChatDate: Wednesday, May 27Time: 2:30 p.m.
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials.
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-00
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously received asciminib, cumulative MMR rate was 52%, with 38% of patients achieving MMR by 24 weeks ELVN-001 maintained a favorable safety and tolerability profile with 141 patients enrolled and a median treatment duration of ~32 weeks EHA presentation will include updated data with additional patients and longer treatment duration BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced additional, positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) in an abstract accepted for an oral presentation at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden and virtually.
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Strong balance sheet with $452 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029 BOULDER, Colo., May 7, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million
Helen Louise Collins exercised and sold 40,000 Common Stock shares over March 9–10, 2026, generating proceeds of ~$1.20 million at a weighted average price of $30.07 per share. The transaction reduced her direct Common Stock holdings by 61.54%, from 65,000 to 25,000 shares, while indirect holdings remained at zero.
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year High – Here’s Why
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) hit a new 52-week high during mid-day trading on Friday. The stock traded as high as $31.76 and last traded at $30.05, with a volume of 4931441 shares. The stock had previously closed at $27.25. Analyst Upgrades and Downgrades A number of analysts have
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $41.00 Consensus PT from Analysts
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month target
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
/PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
BOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m.
Price Targets
Enliven price target raised to $65 from $56 at H.C. Wainwright
$65.00
(was $50.80)
Robert Burns
·
H.C. Wainwright
Enliven price target raised to $80 from $60 at Stifel
$80.00
(was $50.68)
Stifel Nicolaus
Enliven initiated with a Buy at Stifel
$60.00
(was $33.63)
Stifel Nicolaus
Enliven Therapeutics (ELVN) PT Raised to $62 at Mizuho
$62.00
(was $37.51)
Salim Syed
·
Mizuho Securities
Enliven initiated with a Buy at Guggenheim
$80.00
(was $39.59)
Guggenheim
Enliven price target raised to $59 from $41 at Goldman Sachs
$59.00
(was $42.45)
Goldman Sachs
Enliven price target raised to $52 from $40 at Baird
$52.00
(was $23.09)
Colleen Kusy
·
Robert W. Baird
Enliven price target raised to $39 from $37 at H.C. Wainwright
$39.00
(was $21.08)
H.C. Wainwright
Enliven Therapeutics (ELVN) PT Raised to $40 at Baird
$40.00
(was $24.05)
Colleen Kusy
·
Robert W. Baird
Mizuho Reiterates Outperform Rating on Enliven Therapeutics (ELVN)
$39.00
(was $23.80)
Salim Syed
·
Mizuho Securities
Baird Starts Enliven Therapeutics (ELVN) at Outperform
$32.00
(was $22.58)
Colleen Kusy
·
Robert W. Baird
Mizuho Starts Enliven Therapeutics (ELVN) at Buy
$34.00
(was $18.30)
Salim Syed
·
Mizuho Securities